Grace Therapeutics, Inc (GRCE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Grace Therapeutics, Inc (GRCE) is down 27.8% since the beginning of the year. At $3 per share, GRCE is trading 51.7% below its 52-week high of $5.

Grace Therapeutics, Inc (GRCE) has returned -27.75% so far this year and -11.03% over the past 12 months.

Based on dividend-adjusted daily data since Oct 8, 2024, GRCE's average daily return is +0.07%, while the average monthly return is +0.61%. At this rate, an investment would double in approximately 9.5 years.

Historically, 67% of months were positive and 33% were negative. The best month was Feb 2026 with a return of +18.2%, while the worst month was Apr 2026 at -51.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 3 months.

On a daily basis, GRCE closed higher 50% of trading days. The best single day was Dec 4, 2024 with a return of +20.0%, while the worst single day was Apr 23, 2026 at -45.5%.

Grace Therapeutics, Inc has an annualized alpha of 1.36%, beta of 0.92, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since October 09, 2024.

• This stock tended to rise when S&P 500 Index fell (downside capture of -203.78%), but participation in market rallies was also limited (-64.60%) - a profile typical of counter-cyclical assets.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

GRCE ranks 35 for risk / return — below 35% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Grace Therapeutics, Inc (GRCE) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Grace Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Grace Therapeutics, Inc was 60.00%, occurring on Apr 7, 2025. Recovery took 242 trading sessions.

The current Grace Therapeutics, Inc drawdown is 51.27%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Grace Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Grace Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.